{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:42Z","timestamp":1792244922336,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11154-024-09909-6","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T06:01:43Z","timestamp":1727071303000},"page":"1003-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug induced hypoprolactinemia"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-9802","authenticated-orcid":false,"given":"Adriana G.","family":"Ioachimescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahrettin","family":"Kelestimur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"9909_CR1","doi-asserted-by":"publisher","first-page":"16092","DOI":"10.1038\/nrdp.2016.92","volume":"2","author":"Z Karaca","year":"2016","unstructured":"Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F. Sheehan syndrome. Nat Rev Dis Primers. 2016;2:16092. https:\/\/doi.org\/10.1038\/nrdp.2016.92.","journal-title":"Nat Rev Dis Primers"},{"key":"9909_CR2","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523\u2013631. https:\/\/doi.org\/10.1152\/physrev.2000.80.4.1523.","journal-title":"Physiol Rev"},{"key":"9909_CR3","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s40618-023-02101-8","volume":"46","author":"E Maseroli","year":"2023","unstructured":"Maseroli E, Verde N, Cipriani S, Rastrelli G, Alfaroli C, Ravelli SA, et al. Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile. J Endocrinol Invest. 2023;46:2481\u201392. https:\/\/doi.org\/10.1007\/s40618-023-02101-8.","journal-title":"J Endocrinol Invest"},{"key":"9909_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12020-023-03375-x","volume":"81","author":"G Spaggiari","year":"2023","unstructured":"Spaggiari G, Costantino F, Granata ARM, Tagliavini S, Canu G, Varani M, et al. Prolactin and spermatogenesis: new lights on the interplay between prolactin and sperm parameters. Endocrine. 2023;81:330\u20139. https:\/\/doi.org\/10.1007\/s12020-023-03375-x.","journal-title":"Endocrine"},{"key":"9909_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jsm.12327","volume":"11","author":"G Corona","year":"2014","unstructured":"Corona G, Wu FC, Rastrelli G, Lee DM, Forti G, O\u2019Connor DB, et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med. 2014;11:240\u201353. https:\/\/doi.org\/10.1111\/jsm.12327.","journal-title":"J Sex Med"},{"key":"9909_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09892-y","author":"V Munro","year":"2024","unstructured":"Munro V, Wilkinson M, Imran SA. Neuropsychological complications of hypoprolactinemia. Rev Endocr Metab Disord. 2024. https:\/\/doi.org\/10.1007\/s11154-024-09892-y.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR7","doi-asserted-by":"publisher","unstructured":"Karaca Z, Unluhizarci K, Kelestimur F, Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus: absence of proof is not the proof of absence. Rev Endocr Metab Disord 2023. https:\/\/doi.org\/10.1007\/s11154-023-09847-9.","DOI":"10.1007\/s11154-023-09847-9"},{"key":"9909_CR8","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1530\/JOE-15-0213","volume":"226","author":"DR Grattan","year":"2015","unstructured":"Grattan DR. 60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-prolactin axis. J Endocrinol. 2015;226:T101\u2013122. https:\/\/doi.org\/10.1530\/JOE-15-0213.","journal-title":"J Endocrinol"},{"key":"9909_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1210\/jcem-67-1-116","volume":"67","author":"JD Veldhuis","year":"1988","unstructured":"Veldhuis JD, Johnson ML. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 1988;67:116\u201323. https:\/\/doi.org\/10.1210\/jcem-67-1-116.","journal-title":"J Clin Endocrinol Metab"},{"key":"9909_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1210\/edrv-17-6-639","volume":"17","author":"N Ben-Jonathan","year":"1996","unstructured":"Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639\u201369. https:\/\/doi.org\/10.1210\/edrv-17-6-639.","journal-title":"Endocr Rev"},{"key":"9909_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/EJE-09-0923","volume":"162","author":"Z Karaca","year":"2010","unstructured":"Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F. Pregnancy and pituitary disorders. Eur J Endocrinol. 2010;162:453\u201375. https:\/\/doi.org\/10.1530\/EJE-09-0923.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0025-6196(12)60946-x","volume":"65","author":"BW Scheithauer","year":"1990","unstructured":"Scheithauer BW, Sano T, Kovacs KT, Young WF Jr., Ryan N, Randall RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc. 1990;65:461\u201374. https:\/\/doi.org\/10.1016\/s0025-6196(12)60946-x.","journal-title":"Mayo Clin Proc"},{"key":"9909_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15:356\u201365. https:\/\/doi.org\/10.1038\/s41574-019-0194-6.","journal-title":"Nat Rev Endocrinol"},{"key":"9909_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12884-016-0937-5","volume":"16","author":"H Schock","year":"2016","unstructured":"Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HA, Idahl A, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16:146. https:\/\/doi.org\/10.1186\/s12884-016-0937-5.","journal-title":"BMC Pregnancy Childbirth"},{"key":"9909_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1152\/physrev.1990.70.2.279","volume":"70","author":"SW Lamberts","year":"1990","unstructured":"Lamberts SW, Macleod RM. Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev. 1990;70:279\u2013318. https:\/\/doi.org\/10.1152\/physrev.1990.70.2.279.","journal-title":"Physiol Rev"},{"key":"9909_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724\u201363. https:\/\/doi.org\/10.1210\/edrv.22.6.0451.","journal-title":"Endocr Rev"},{"key":"9909_CR17","doi-asserted-by":"publisher","first-page":"110679","DOI":"10.1016\/j.mce.2019.110679","volume":"502","author":"HR Phillipps","year":"2020","unstructured":"Phillipps HR, Yip SH, Grattan DR. Patterns of prolactin secretion. Mol Cell Endocrinol. 2020;502:110679. https:\/\/doi.org\/10.1016\/j.mce.2019.110679.","journal-title":"Mol Cell Endocrinol"},{"key":"9909_CR18","first-page":"97","volume":"63","author":"M Holzbauer","year":"1985","unstructured":"Holzbauer M, Racke K. The dopaminergic innervation of the intermediate lobe and of the neural lobe of the pituitary gland. Med Biol. 1985;63:97\u2013116.","journal-title":"Med Biol"},{"key":"9909_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1126\/science.7256264","volume":"213","author":"LL Peters","year":"1981","unstructured":"Peters LL, Hoefer MT, Ben-Jonathan N. The posterior pituitary: regulation of anterior pituitary prolactin secretion. Science. 1981;213:659\u201361. https:\/\/doi.org\/10.1126\/science.7256264.","journal-title":"Science"},{"key":"9909_CR20","doi-asserted-by":"publisher","first-page":"E10216","DOI":"10.1073\/pnas.1713897114","volume":"114","author":"J Clarkson","year":"2017","unstructured":"Clarkson J, Han SY, Piet R, McLennan T, Kane GM, Ng J, et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A. 2017;114:E10216\u201323. https:\/\/doi.org\/10.1073\/pnas.1713897114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9909_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/en.2010-0668","volume":"152","author":"IC Kokay","year":"2011","unstructured":"Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152:526\u201335. https:\/\/doi.org\/10.1210\/en.2010-0668.","journal-title":"Endocrinology"},{"key":"9909_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/BF03346292","volume":"30","author":"Y Toledano","year":"2007","unstructured":"Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30:268\u201373. https:\/\/doi.org\/10.1007\/BF03346292.","journal-title":"J Endocrinol Invest"},{"key":"9909_CR23","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1210\/jc.2005-2491","volume":"91","author":"A Mukherjee","year":"2006","unstructured":"Mukherjee A, Ryder WD, Jostel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults. J Clin Endocrinol Metab. 2006;91:2520\u20135. https:\/\/doi.org\/10.1210\/jc.2005-2491.","journal-title":"J Clin Endocrinol Metab"},{"key":"9909_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1365-2265.2003.01916.x","volume":"59","author":"A Mukherjee","year":"2003","unstructured":"Mukherjee A, Murray RD, Columb B, Gleeson HK, Shalet SM. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol (Oxf). 2003;59:743\u20138. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01916.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9909_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11102-024-01393-0","volume":"27","author":"I Uzun","year":"2024","unstructured":"Uzun I, Karaca Z, Hacioglu A, Unluhizarci K, Kelestimur F. The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary. 2024;27:277\u201386. https:\/\/doi.org\/10.1007\/s11102-024-01393-0.","journal-title":"Pituitary"},{"key":"9909_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/neu.2013.3002","volume":"31","author":"A Kopczak","year":"2014","unstructured":"Kopczak A, Kilimann I, von Rosen F, Krewer C, Schneider HJ, Stalla GK, et al. Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage. J Neurotrauma. 2014;31:99\u2013107. https:\/\/doi.org\/10.1089\/neu.2013.3002.","journal-title":"J Neurotrauma"},{"key":"9909_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1530\/EJE-14-0244","volume":"171","author":"H Diri","year":"2014","unstructured":"Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC, et al. Extensive investigation of 114 patients with Sheehan\u2019s syndrome: a continuing disorder. Eur J Endocrinol. 2014;171:311\u20138. https:\/\/doi.org\/10.1530\/EJE-14-0244.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR28","doi-asserted-by":"publisher","unstructured":"Han TS, Antonio L, Bartfai G, O\u2019Neill TW, Punab M, Rastrelli G et al. Evidence-based definition of hypoprolactinemia in European men aged 40\u201386 years: the European male ageing study. Rev Endocr Metab Disord 2024. https:\/\/doi.org\/10.1007\/s11154-024-09890-0.","DOI":"10.1007\/s11154-024-09890-0"},{"key":"9909_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09896-8","author":"E Urhan","year":"2024","unstructured":"Urhan E, Karaca Z. Diagnosis of hypoprolactinemia. Rev Endocr Metab Disord. 2024. https:\/\/doi.org\/10.1007\/s11154-024-09896-8.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904\u20139. https:\/\/doi.org\/10.1056\/NEJM199410063311403.","journal-title":"N Engl J Med"},{"key":"9909_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19:722\u201340. https:\/\/doi.org\/10.1038\/s41574-023-00886-5.","journal-title":"Nat Rev Endocrinol"},{"key":"9909_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","volume":"37","author":"J Webster","year":"1992","unstructured":"Webster J, Piscitelli G, Polli A, D\u2019Alberton A, Falsetti L, Ferrari C, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline dose-finding Study Group. Clin Endocrinol (Oxf). 1992;37:534\u201341. https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb01485.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9909_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273\u201388. https:\/\/doi.org\/10.1210\/jc.2010-1692.","journal-title":"J Clin Endocrinol Metab"},{"key":"9909_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","volume":"185","author":"B Biagetti","year":"2021","unstructured":"Biagetti B, Sarria-Estrada S, Ng-Wong YK, Martinez-Saez E, Casteras A, Cordero Asanza E, et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur J Endocrinol. 2021;185:587\u201395. https:\/\/doi.org\/10.1530\/EJE-21-0561.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR35","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1016\/j.wneu.2019.05.249","volume":"129","author":"OO Akinduro","year":"2019","unstructured":"Akinduro OO, Lu VM, Izzo A, De Biase G, Vilanilam G, Van Gompel JJ, et al. Radiographic and Hormonal Regression in Prolactinomas: an analysis of treatment failure. World Neurosurg. 2019;129:e686\u201394. https:\/\/doi.org\/10.1016\/j.wneu.2019.05.249.","journal-title":"World Neurosurg"},{"key":"9909_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","volume":"49","author":"EA Giraldi","year":"2020","unstructured":"Giraldi EA, Ioachimescu AG. The role of dopamine agonists in Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020;49:453\u201374. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.006.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"9909_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","volume":"60","author":"K Suda","year":"2013","unstructured":"Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60:507\u201315.","journal-title":"Endocr J"},{"key":"9909_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1530\/eje.1.01888","volume":"152","author":"D Selvarajah","year":"2005","unstructured":"Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569\u201374. https:\/\/doi.org\/10.1530\/eje.1.01888.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000317314","volume":"92","author":"P Mattar","year":"2010","unstructured":"Mattar P, Alves Martins MR, Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology. 2010;92:120\u20137. https:\/\/doi.org\/10.1159\/000317314.","journal-title":"Neuroendocrinology"},{"key":"9909_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2265.2004.02082.x","volume":"61","author":"R Cozzi","year":"2004","unstructured":"Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61:209\u201315. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02082.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9909_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21:667\u201378. https:\/\/doi.org\/10.1007\/s11154-020-09588-z.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR42","doi-asserted-by":"publisher","first-page":"1165681","DOI":"10.3389\/fendo.2023.1165681","volume":"14","author":"RA Feelders","year":"2023","unstructured":"Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonzalez-Devia D, Boguszewski CL, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease. Front Endocrinol (Lausanne). 2023;14:1165681. https:\/\/doi.org\/10.3389\/fendo.2023.1165681.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9909_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-15-0807","volume":"174","author":"P Burman","year":"2016","unstructured":"Burman P, Eden-Engstrom B, Ekman B, Karlsson FA, Schwarcz E, Wahlberg J. Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016;174:17\u201324. https:\/\/doi.org\/10.1530\/EJE-15-0807.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21:631\u201341. https:\/\/doi.org\/10.1007\/s11102-018-0897-z.","journal-title":"Pituitary"},{"key":"9909_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-022-04149-7","volume":"160","author":"P Iglesias","year":"2022","unstructured":"Iglesias P, Biagetti B, Araujo-Castro M, Alcazar V, Guerrero-Perez F, Rivero N, et al. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol. 2022;160:351\u20139. https:\/\/doi.org\/10.1007\/s11060-022-04149-7.","journal-title":"J Neurooncol"},{"key":"9909_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-023-01365-w","volume":"27","author":"I Ayalon-Dangur","year":"2024","unstructured":"Ayalon-Dangur I, Turjeman A, Hirsch D, Robenshtok E, Tsvetov G, Gorshtein A, et al. Cabergoline treatment for surgery-naive non-functioning pituitary macroadenomas. Pituitary. 2024;27:52\u201360. https:\/\/doi.org\/10.1007\/s11102-023-01365-w.","journal-title":"Pituitary"},{"key":"9909_CR47","doi-asserted-by":"publisher","first-page":"e3836","DOI":"10.1002\/dmrr.3836","volume":"40","author":"T Wu","year":"2024","unstructured":"Wu T, Duan Y, Jiang J, Gu T, Zhang P, Bi Y. A Century of Prolactin: emerging perspectives as a Metabolic Regulator. Diabetes Metab Res Rev. 2024;40:e3836. https:\/\/doi.org\/10.1002\/dmrr.3836.","journal-title":"Diabetes Metab Res Rev"},{"key":"9909_CR48","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520. https:\/\/doi.org\/10.3389\/fendo.2022.1015520.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9909_CR49","doi-asserted-by":"publisher","first-page":"1002320","DOI":"10.3389\/fendo.2022.1002320","volume":"13","author":"P Kirsch","year":"2022","unstructured":"Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: a review. Front Endocrinol (Lausanne). 2022;13:1002320. https:\/\/doi.org\/10.3389\/fendo.2022.1002320.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9909_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09891-z","author":"RS Auriemma","year":"2024","unstructured":"Auriemma RS, Scairati R, Pirchio R, Del Vecchio G, Di Meglio S, Menafra D, et al. Cardiometabolic effects of hypoprolactinemia. Rev Endocr Metab Disord. 2024. https:\/\/doi.org\/10.1007\/s11154-024-09891-z.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","volume":"44","author":"SS Inancli","year":"2013","unstructured":"Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013;44:193\u20139. https:\/\/doi.org\/10.1007\/s12020-012-9857-y.","journal-title":"Endocrine"},{"key":"9909_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11011-016-9882-2","volume":"32","author":"V Schwetz","year":"2017","unstructured":"Schwetz V, Librizzi R, Trummer C, Theiler G, Stiegler C, Pieber TR, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32:155\u201361. https:\/\/doi.org\/10.1007\/s11011-016-9882-2.","journal-title":"Metab Brain Dis"},{"key":"9909_CR53","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM dos Santos Silva","year":"2011","unstructured":"dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obes (Silver Spring). 2011;19:800\u20135. https:\/\/doi.org\/10.1038\/oby.2010.150.","journal-title":"Obes (Silver Spring)"},{"key":"9909_CR54","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1530\/EC-19-0286","volume":"8","author":"S Byberg","year":"2019","unstructured":"Byberg S, Futtrup J, Andreassen M, Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect. 2019;8:1395\u2013404. https:\/\/doi.org\/10.1530\/EC-19-0286.","journal-title":"Endocr Connect"},{"key":"9909_CR55","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4158\/EP12187.OR","volume":"18","author":"AI Vinik","year":"2012","unstructured":"Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931\u201343. https:\/\/doi.org\/10.4158\/EP12187.OR.","journal-title":"Endocr Pract"},{"key":"9909_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4158\/EP12325.OR","volume":"19","author":"AJ Garber","year":"2013","unstructured":"Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo-Jack S. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013;19:100\u20136. https:\/\/doi.org\/10.4158\/EP12325.OR.","journal-title":"Endocr Pract"},{"key":"9909_CR57","doi-asserted-by":"publisher","first-page":"1001703","DOI":"10.3389\/fendo.2022.1001703","volume":"13","author":"Y Macotela","year":"2022","unstructured":"Macotela Y, Ruiz-Herrera X, Vazquez-Carrillo DI, Ramirez-Hernandez G, de la Martinez G, Clapp C. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703. https:\/\/doi.org\/10.3389\/fendo.2022.1001703.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9909_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09886-w","author":"G Ken-Dror","year":"2024","unstructured":"Ken-Dror G, Fluck D, Lean MEJ, Casanueva FF, Han TS. The relationship between low prolactin and type 2 diabetes. Rev Endocr Metab Disord. 2024. https:\/\/doi.org\/10.1007\/s11154-024-09886-w.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR59","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/17446651.2022.2144829","volume":"17","author":"G Corona","year":"2022","unstructured":"Corona G, Rastrelli G, Comeglio P, Guaraldi F, Mazzatenta D, Sforza A, et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab. 2022;17:533\u201345. https:\/\/doi.org\/10.1080\/17446651.2022.2144829.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"9909_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12020-022-03145-1","volume":"78","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopien B. Cardiometabolic profile of young women with hypoprolactinemia. Endocrine. 2022;78:135\u201341. https:\/\/doi.org\/10.1007\/s12020-022-03145-1.","journal-title":"Endocrine"},{"key":"9909_CR61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000527333","volume":"147","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopien B. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic effects of Atorvastatin: a pilot study. Cardiology. 2022;147:497\u2013506. https:\/\/doi.org\/10.1159\/000527333.","journal-title":"Cardiology"},{"key":"9909_CR62","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11154-022-09753-6","volume":"23","author":"A Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos NA. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord. 2022;23:1089\u201399. https:\/\/doi.org\/10.1007\/s11154-022-09753-6.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80:863\u20138. https:\/\/doi.org\/10.1111\/cen.12375.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9909_CR64","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","volume":"27","author":"MH Almalki","year":"2024","unstructured":"Almalki MH, Alsuraikh MA, Almalki E, Aziz F, Almazrouei R, AlDahmani KM, et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. 2024;27:197\u2013203. https:\/\/doi.org\/10.1007\/s11102-024-01383-2.","journal-title":"Pituitary"},{"key":"9909_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180:31\u201340. https:\/\/doi.org\/10.1530\/EJE-18-0682.","journal-title":"Eur J Endocrinol"},{"key":"9909_CR66","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0009-9236(95)90253-8","volume":"58","author":"CS Ufearo","year":"1995","unstructured":"Ufearo CS, Orisakwe OE. Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. Clin Pharmacol Ther. 1995;58:354\u20139. https:\/\/doi.org\/10.1016\/0009-9236(95)90253-8.","journal-title":"Clin Pharmacol Ther"},{"key":"9909_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11154-015-9322-3","volume":"16","author":"G Rastrelli","year":"2015","unstructured":"Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16:233\u201348. https:\/\/doi.org\/10.1007\/s11154-015-9322-3.","journal-title":"Rev Endocr Metab Disord"},{"key":"9909_CR68","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6:1457\u201366. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x.","journal-title":"J Sex Med"},{"key":"9909_CR69","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/cen.14283","volume":"93","author":"R Krysiak","year":"2020","unstructured":"Krysiak R, Kowalcze K, Okopien B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020;93:482\u20138. https:\/\/doi.org\/10.1111\/cen.14283.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9909_CR70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2020.04.031","volume":"222","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonzalez-Rodriguez A, Garcia-Rizo C, Crespo-Facorro B, Monreal JA, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020;222:88\u201396. https:\/\/doi.org\/10.1016\/j.schres.2020.04.031.","journal-title":"Schizophr Res"},{"key":"9909_CR71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1089\/cap.2012.0062","volume":"23","author":"DJ Safer","year":"2013","unstructured":"Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23:282\u20139. https:\/\/doi.org\/10.1089\/cap.2012.0062.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"9909_CR72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fpsyt.2020.00152","volume":"11","author":"G Cicala","year":"2020","unstructured":"Cicala G, Barbieri MA, Santoro V, Tata C, Colucci PV, Vanadia F, et al. Safety and tolerability of antipsychotic drugs in Pediatric patients: data from a 1-Year naturalistic study. Front Psychiatry. 2020;11:152. https:\/\/doi.org\/10.3389\/fpsyt.2020.00152.","journal-title":"Front Psychiatry"},{"key":"9909_CR73","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/cap.2021.0140","volume":"32","author":"SM Kroigaard","year":"2022","unstructured":"Kroigaard SM, Clemmensen L, Tarp S, Pagsberg AK. A Meta-analysis of antipsychotic-Induced Hypo- and hyperprolactinemia in children and adolescents. J Child Adolesc Psychopharmacol. 2022;32:374\u201389. https:\/\/doi.org\/10.1089\/cap.2021.0140.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"9909_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3371\/CSRP.PRJA.022015","volume":"9","author":"AJ Propst","year":"2016","unstructured":"Propst AJ, Jarvis GE, Margolese HC. Aripiprazole-Induced Hypoprolactinemia in an adult male with first-episode psychosis. Clin Schizophr Relat Psychoses. 2016;9:173\u20136. https:\/\/doi.org\/10.3371\/CSRP.PRJA.022015.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"9909_CR75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/npr2.12190","volume":"41","author":"M Tasaki","year":"2021","unstructured":"Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41:379\u201384. https:\/\/doi.org\/10.1002\/npr2.12190.","journal-title":"Neuropsychopharmacol Rep"},{"key":"9909_CR76","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/JCP.0000000000000527","volume":"36","author":"R Sogawa","year":"2016","unstructured":"Sogawa R, Shimomura Y, Minami C, Maruo J, Kunitake Y, Mizoguchi Y, et al. Aripiprazole-Associated Hypoprolactinemia in the clinical setting. J Clin Psychopharmacol. 2016;36:385\u20137. https:\/\/doi.org\/10.1097\/JCP.0000000000000527.","journal-title":"J Clin Psychopharmacol"},{"key":"9909_CR77","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","volume":"66","author":"G Nagai","year":"2012","unstructured":"Nagai G, Mihara K, Nakamura A, Suzuki T, Nemoto K, Kagawa S, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012;66:518\u201324. https:\/\/doi.org\/10.1111\/j.1440-1819.2012.02391.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"9909_CR78","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12888-020-02957-7","volume":"20","author":"YW Jen","year":"2020","unstructured":"Jen YW, Hwang TJ, Chan HY, Hsieh MH, Liu CC, Liu CM, et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC Psychiatry. 2020;20:552. https:\/\/doi.org\/10.1186\/s12888-020-02957-7.","journal-title":"BMC Psychiatry"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09909-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-024-09909-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09909-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T15:06:45Z","timestamp":1733584005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-024-09909-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9909"],"URL":"https:\/\/doi.org\/10.1007\/s11154-024-09909-6","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"6 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}